Dr. Amy L. Gryshuk received her Bachelor of Science degree in Chemistry at Saint Francis University in Loretto, PA in 2000.  She subsequently joined the Department of Molecular Pharmacology & Cancer Therapeutics at Roswell Park Cancer Institute – a Division of The State University of New York at Buffalo as a predoctoral student from 2000-2005.  From 2003-2005 she received an Integrated Graduate Education Research Traineeship in Biophotonics.  Her doctoral thesis analyzed fluorinated and non-fluorinated photosensitizers as potential ‘bi-functional’ agents for the diagnosis and treatment of cancer via photodynamic therapy.  This work has led to numerous publications in scientific texts and peer-reviewed journals.  With successful completion of her thesis in 2005, Amy accepted a position as a postdoctoral researcher with the University of California, Davis – Center for Biophotonics from 2005 to 2006.  During the first year of her postdoctoral position she designed and evaluated novel bioluminescent substrates for bioluminescence-based protease assays.  This was a highly collaborative project between CBST, Stanford University and Lawrence Livermore National Laboratory (LLNL).  From 2006 to 2008, she transferred into the Chemistry, Materials, Earth and Life Sciences – Biosciences & Biotechnology Division at LLNL continuing on the medical biophotonics CBST-funded project, as well as integrating into a short-lived bio-security project at LLNL.

Following completion of her postdoctoral position in August 2008, Dr. Gryshuk joined CBST in September 2008 as a University of California, Davis Discovery Fellow funded by the Industry-University Cooperative Research Program.  As the Director of New Ventures (DNV) she will use her scientific expertise and co-inventor status on two submitted patents to evaluate measures for developing a viable sustainability model for our National Science Foundation sponsored Center of Excellence in Biophotonics.  Her focus is on the ever increasing need for establishing a viable model for translating university-based research to product opportunities that could impact the practice of clinical medicine.